Sign up to save your podcasts
Or
Share Tulisokibart, a New Drug for Moderate-to-Severe UC That May Come With Personalized Medicine
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Tulisokibart, a New Drug for Moderate-to-Severe UC That May Come With Personalized Medicine
Ellen Axenfeld, MD and Elie Al Zazzi, MD, MPH discuss "Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis,” by Sands BE, Feagan BG, Peyrin-Biroulet L, et al and the ARTEMIS-UC Study Group. Published in N Engl J Med. 2024 Sep 26;391(12):1119-1129.
View all episodes
By American College of Gastroenterology
4.7
1515 ratings
Ellen Axenfeld, MD and Elie Al Zazzi, MD, MPH discuss "Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis,” by Sands BE, Feagan BG, Peyrin-Biroulet L, et al and the ARTEMIS-UC Study Group. Published in N Engl J Med. 2024 Sep 26;391(12):1119-1129.
More shows like Evidence-Based GI: An ACG Publication and Podcast
View all
JAMA Editors' Summary
129 Listeners
Gut Podcast
8 Listeners
American Journal of Gastroenterology Author Podcasts
69 Listeners
JAMA Clinical Reviews
487 Listeners
White Coat Investor Podcast
2,416 Listeners
The Curbsiders Internal Medicine Podcast
3,317 Listeners
Core IM | Internal Medicine Podcast
1,090 Listeners
Annals On Call Podcast
184 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
Run the List
243 Listeners
Behind the Case: An ACG Case Reports Journal Podcast
6 Listeners
Listen In: GI Endoscopy
33 Listeners
Inside Scope
6 Listeners
Gastroenterology Learning Network
10 Listeners
Gastroenterology & Endoscopy
3 Listeners